|
1
|
Chadwick RB, Jiang GL, Bennington GA, Yuan
B, Johnson CK, Stevens MW, Niemann TH, Peltomaki P, Huang S and de
la Chapelle A: Candidate tumor suppressor RIZ is frequently
involved in colorectal carcinogenesis. Proc Natl Acad Sci USA.
97:2662–2667. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang GL and Huang S: Adenovirus
expressing RIZ1 in tumor suppressor gene therapy of
microsatellite-unstable colorectal cancers. Cancer Res.
61:1796–1798. 2001.PubMed/NCBI
|
|
3
|
Mandelbaum J, Bhagat G, Tang H, Mo T,
Brahmachary M, Shen Q, Chadburn A, Rajewsky K, Tarakhovsky A,
Pasqualucci L and Dalla-Favera R: BLIMP1 is a tumor suppressor gene
frequently disrupted in activated B cell-like diffuse large B cell
lymphoma. Cancer Cell. 18:568–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wieser R: The oncogene and developmental
regulator EVI1: Expression, biochemical properties, and biological
functions. Gene. 396:346–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shing DC, Trubia M, Marchesi F, Radaelli
E, Belloni E, Tapinassi C, Scanziani E, Mecucci C, Crescenzi B,
Lahortiga I, et al: Overexpression of sPRDM16 coupled with loss of
p53 induces myeloid leukemias in mice. J Clin Invest.
117:3696–3707. 2007.PubMed/NCBI
|
|
6
|
Deng Q and Huang S: PRDM5 is silenced in
human cancers and has growth suppressive activities. Oncogene.
23:4903–4910. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meani N, Pexximenti F, Deflorian G, Mione
M and Alcalay M: The tumor suppressor PRDM5 regulates Wnt signaling
at early stages of zebrafish development. PLoS One. 4:e42732009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burkitt Wright EMM, Spencer HL, Daly SB,
Manson FDC, Zeef LAH, Urquhart J, Zoppi N, Bonshek R, Tosounidis I,
et al: Mutations in PRDM5 in brittle cornea syndrome identify a
pathway regulating extracellular matrix development and
maintenance. Am J Hum Genet. 88:767–777. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
10
|
Hohenauer T and Moore AW: The Prdm family:
Expanding roles in stem cells and development. Development.
139:2267–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang JC, Meredith DM, Mayer PR, Borromeo
MD, Lai HC, Ou YH and Johnson JE: Prdm13 mediates the balance of
inhibitory and excitatory neurons in somatosensory circuits. Dev
Cell. 25:182–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bäumer N, Tickenbrock L, Tschanter P,
Lohmeyer L, Diederichs S, Bäumer S, Skryabin BV, Zhang F,
Agrawal-Singh S, Köhler G, et al: Inhibitor of cyclin-dependent
kinase (CDK) interacting with cyclin A1 (INCA1) regulates
proliferation and is repressed by oncogenic signaling. J Biol Chem.
286:28210–28222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moncada-Pazos A, Obaya AJ, Fraga MF,
Viloria CG, Capellá G, Gausachs M, Esteller M, López-Otín C and Cal
S: The ADAMTS12 metalloprotease gene is epigenetically silenced in
tumor cells and transcriptionally activated in the stroma during
progression of colon cancer. J Cell Sci. 122:2906–2913. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El Hour M, Moncada-Pazos A, Blacher S,
Masset A, Cal S, Berndt S, Detilleux J, Host L, Obaya AJ, Maillard
C, et al: Higher sensitivity of Adamts12-deficient mice to tumor
growth and angiogenesis. Oncogene. 29:3025–3032. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang D, Zhu T, Zhang FB and He C:
Expression of ADAMTS12 in colorectal cancer-associated stroma
prevents cancer development and is a good prognostic indicator of
colorectal cancer. Dig Dis Sci. 56:3281–3287. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Zhu W, Su X, Wu S, Lin Y, Li J,
Wang Y, Chen J, Zhou Y, Qiu P, et al: Triprolide inhibits
proliferation and invasion of malignant glioma cells. J Neurooncol.
109:53–62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmitz AA, Govek EE, Böttner B and Van
Aelst L: Rho GTPases: Signaling, migration, and invasion. Exp Cell
Res. 261:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Qian J, Hu Y, Kong X, Chen H, Shi
Q, Jiang L, Wu C, Zou W, Chen Y, et al: ArhGAP30 promotes p53
acetylation and function in colorectal cancer. Nat Commun.
5:47352014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
20
|
Qian X1, Li G, Asmussen HK, Asnaghi L,
Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG and Lowy
DR: Oncogenic inhibition by a deleted in liver cancer gene requires
cooperation between tensin binding and Rho-specific
GTPase-activating protein activities. Proc Natl Acad Sci USA.
104:9012–9017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan BZ, Jefferson AM, Baldwin KT,
Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as
tumor suppressor gene in human non-small cell lung carcinomas.
Oncogene. 23:1405–1411. 2004. View Article : Google Scholar
|
|
22
|
Karnoub AE, Symons M, Campbell SL and Der
CJ: Molecular basis for Rho GTPase signaling specificity. Breast
Cancer Res Treat. 84:61–71. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ridley AJ: Rho proteins and cancer. Breast
Cancer Res Treat. 84:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gómez del Pulgar T, Benitah SA, Valerón
PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis:
Evidence for a significant link. Bioessays. 27:602–613. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Integrated genomic analysis identifies clinically relevant subtypes
of glioblastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
